Estimating the treatment effect in patients with gastric cancer in the presence of noncompliance
Gastroenterology and Hepatology from Bed to Bench,
26 April 2021
Aim: In this study, these methods were used to estimate the treatment effect in patients with gastric cancer in the presence of noncompliance.
Background: In medical sciences, simple and advanced methods are used to estimate treatment effects in the presence of noncompliance.
Methods: This historical cohort study surveyed 178 patients with gastric cancer underwent chemotherapy alone (chemotherapy alone group) and 193 patients underwent surgery and chemotherapy (surgery plus chemotherapy group) from 2003 to 2007 at the Cancer Institute of Imam Khomeini Hospital (Tehran). Demographic and clinical characteristics were extracted from patients' hospital records. The survival of patients was calculated as being from diagnosis to death or to the end of the study. The treatment effect was estimated using three methods: treatment as a time-dependent covariate, IPCW, and Structural Nested Models using STATA and R software.
Results: Fifty-six patients (31.5%) who underwent chemotherapy and 69 patients (35.8%) who underwent surgery and chemotherapy died by the end of the study. The hazard ratio in group I compared to group II was estimated between 1.5 to 2.07 times based on the simple analysis method. The modified hazard ratio was estimated to be 1.21 (95% CI: 1.11-1.32) based on the SNM method. Surgery plus chemotherapy is superior to chemotherapy alone, and it improves the overall survival (OS) rate of gastric cancer patients.
Conclusion: Survival was improved in patients undergoing chemotherapy and surgery together compared to those undergoing chemotherapy alone. The results of the current study suggest that treatment effect can be estimated unbiasedly using the appropriate method.
Keywords: Treatment effect, Noncompliance, Time-dependent covariate, Inverse probability of censoring weights, Structural nested model.
(Please cite as: Safari M, Mahjub H, Esmaeili H, Sadighi S, Roshanaei Gh. Estimating the treatment effect in patients with gastric cancer in the presence of noncompliance. Gastroenterol Hepatol Bed Bench 2021;14(3):206-214).
- Keywords: Treatment effect, Non-compliance, PP, ITT, SNM
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68:394-424.
Fattahi S, Nikbakhsh N, Taheri H, Ghadami E, Kosari-Monfared M, Amirbozorgi G. Prevalence of multiple infections and the risk of gastric adenocarcinoma development at earlier age. Diagn Microbiol Infect Dis 2018; 92:62-8.
Latimer NR, Abrams KR, Lambert PC, Crowther MJ, Wailoo AJ, Morden JP, et al. Adjusting survival time estimates to account for treatment switching in randomized controlled trials--an economic evaluation context: methods, limitations, and recommendations. Med Decis Making 2014; 34:387-402.
Latimer NR, Abrams KR, Lambert PC, Crowther MJ, Wailoo AJ, Morden JP, et al. Adjusting for treatment switching in randomized controlled trials – a simulation study and a simplified two-stage method. Stat Methods Med Res 2017; 26:724-51.
Sommer A, Zeger S. On estimating efficacy from clinical trials. Statistics Med 1991; 10:45-52.
Latimer N. Treatment switching in oncology trials and the acceptability of adjustment methods. Expert Rev Pharmacoecon Outcomes Res 2015; 15:561-4.
Blay J. Pharmacological management of gastrointestinal stromal tumors: an update on the role of sunitinib. Ann Oncol 2010; 21:208-15.
Hernan MA, Cole SR, Margolick J, Cohen M, Robins JM. Structural accelerated failure time models for survival analysis in studies with time-varying treatments. Pharmacoepidemiol Drug Saf 2005;14:477-91.
Cole SR, Hernán MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol 2008; 168:656-64.
Robins J, Finkelstein D. Correcting for Noncompliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics 2000; 56:779-88.
Picciotto S, Hernán M, Page J, Young J, Robins J. Structural Nested Cumulative Failure Time Models to Estimate the Effects of Interventions. J Am Stat Assoc 2012; 107:886-900.
Young J, Hernan M, Picciotto S, Robins J. Relation between three classes of structural models for the effect of a time-varying exposure on survival. Lifetime Data Analysis 2010; 16:71-84.
Roshanaei G, Kazemnejad A, Sadighi S. Determination of Affected Risk Factors on Time to Recurrence and Death in Patients with Postoperative Gastric Cancer using Copula Function. J Res Health Sci 2014; 14:52-6.
Paknazar F, Mahmoudi M, Mohammad K, Zeraati H, and Mansournia M, Yaseri M. Postoperative net survival of gastric adenocarcinoma at Imam Khomeini hospital in Tehran: Estimating in a relative-survival framework. Koomesh 2018; 20:638-44.
Pajouheshnia R, Schuster NA, Groenwold RHH, Rutten FH, Moons KGM, Peelen LM. Accounting for time-dependent treatment use when developing a prognostic model from observational data: A review of methods. Stat Neerlandica 2020; 74:38-51.
Yamaguchi T, Ohashi Y. Adjusting for differential proportions of second-line treatment in cancer clinical trials. Part I: structural nested models and marginal structural models to test and estimate treatment arm effects. Stat Med 2004; 23:1991-2003.
Sterne JAC, Tilling K. G-estimation of causal effects, allowing for time-varying confounding. Stata J 2002; 2:164-82.
Latimer N, Abrams K, Lambert P, Morden J, Crowther M. Assessing methods for dealing with treatment switching in clinical trials: A follow-up simulation study. Stat Methods Med Res 2018; 27:765-84.
Wu Y, Zhao L, Hou Y, Li K, Zhou X. Correcting for Noncompliance in randomized non-inferiority trials with active and placebo control using Structural models. Stat Med 2015; 34:950-65.
Zhang J, Chen C. Correcting treatment effect for treatment switching in randomized oncology trials with a modified iterative parametric estimation method. Stat Med 2016;35:3690-703.
Li L, Tang S, Jiang L. On an enhanced rank-preserving structural failure time model to handle treatment switch, cross-over, and dropout. Stat Med 2017; 36:1532-47.
Shi T, Song X, Liu Q, Yang Y, Yu L, Liu B, et al. Survival benefit of palliative gastrectomy followed by chemotherapy in stage IV gastric signet ring cell carcinoma patients: A large population-based study. Cancer Med 2019; 8:6010-20.
Li W, Jiang H, Yu Y, Wang Y, Wang Z, Cui Y, et al. Outcomes of gastrectomy following upfront chemotherapy in advanced gastric cancer patients with a single noncurable factor: a cohort study. Cancer Manag Res 2019; 11:2007-13.
Choe HJ, Kim JW, Han SH, Lee JH, Ahn SH, Park DJ, Kim JW, Kim YJ, Lee HS, Kim JH, Kim HH, Lee KW. Conversion Surgery in Metastatic Gastric Cancer and Cancer Dormancy as a Prognostic Biomarker. Cancers (Basel) 2019; 12:86.
Cho JH, Lim JY, Choi AR, Choi SM, Kim JW, Choi SH, et al. Comparison of Surgery Plus Chemotherapy and Palliative Chemotherapy Alone for Advanced Gastric Cancer with Krukenberg Tumor. Cancer Res Treat 2015; 47:697-705.
Yuan SQ, Nie RC, Chen S, Chen XJ, Chen YM, Xu LP, et al. Selective Gastric Cancer Patients with Peritoneal Seeding Benefit from Gastrectomy after Palliative Chemotherapy: A Propensity Score Matching Analysis. J Cancer 2017; 8:2231-7.
Roshanaei G, Kazemnejad A, Sadighi S. Survival estimating following recurrence in gastric cancer patients and its relative factors. Koomesh 2011; 12:223-8.
Roshanaei G, Kazemnejad A, Sadighi S. Assessment of risk factors affecting recurrence of patients with gastric cancer in the presence of informative censoring in Iran. Asian Pac J Cancer Prev 2011; 12:2443-6.
Roshanaei G, Sadighi S, Safari M, Faradmal J. Estimated survival time in gastric cancer patients and its associated factors. Koomesh 2012; 14:47-54.
Wu P, Wang P, Ma B, Yin S, Tan Y, Hou W et al. Palliative gastrectomy plus chemotherapy versus chemotherapy alone for incurable advanced gastric cancer: a meta-analysis. Cancer Manag Res 2018; 10:4759-71.
Wilson J, Connock M, Song F, Yao G, Fry-Smith A, Raftery J. Imatinib forthe treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumors: systematic review and economic evaluation. Health Technol Assess 2005;9:1-142
Bond M, Hoyle M, Moxham T, Napier M, Anderson R. Sunitinib for the treatment of gastrointestinal stromal tumors: a critique of the submission from Pfizer. Health Technol Asses 2009; 13:69-74.
Branson M, Whitehead J. Estimating a treatment effect in survival studies in which patients switch treatment. Stat Med 2002; 21:2449-63.
Morden J, Lambert P, Latimer N, Abrams K, Wailoo A. Assessing methods for dealing with treatment switching in randomized controlled trials: a simulation study. BMC Med Res Methodol 2011; 11:4.
- Abstract Viewed: 0 times
- PDF Downloaded: 0 times